Pure And Cure Healthcare is an API and finished-dose manufacturer based in India. It holds 19 active US drug master files across a filed portfolio of 11 molecules. Its filings concentrate with CDSCO (India) and FDA (GH). Its most recent recorded inspection, by US FDA, closed on 25 September 2015 as VAI. Customs aggregates show $2.8M of exports covering 134 molecules to 14 destinations in 2025.
NAI means no action indicated, VAI means voluntary action indicated, and OAI means official action indicated.
| Site | FDA FEI |
|---|---|
| India, India | 3007577941 |
| Panchkula, India | 3024206690 |
| India, India | 3008176882 |
| Molecule | Regulators | Docs |
|---|---|---|
| Cefuroxime | US FDA | 9 |
| Bosentan | US FDA | 1 |
| Cefalotin | US FDA | 1 |
| Cefixime | US FDA | 1 |
| Cefpodoxime | US FDA | 1 |
| Cefprozil | US FDA | 1 |
| Ceftazidime | US FDA | 1 |
| Ceftizoxime | US FDA | 1 |
| Deferasirox | US FDA | 1 |
| Oxacillin | US FDA | 1 |
| Pentosan Polysulfate Sodium | US FDA | 1 |
Also appears on these molecule pages
| Regulator | Filings | GMP certificates |
|---|---|---|
| CDSCO (India) | 94 | None |
| FDA (GH) | 1 | None |
| Year | Revenue | Exports | Destinations |
|---|---|---|---|
| 2026 YTD | Not reported | $377K | 4 |
| 2025 | Not reported | $2.8M | 14 |
| 2024 | Not reported | $2.8M | 15 |
Export figures are customs aggregates. We do not publish the identity of any buyer.
Choose your molecules and target markets. Pure And Cure Healthcare comes back tiered against every other supplier able to file there.
Start for free